Viewing nowCombinationJanudam MX SR Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.

MFDS item code 202201955 · Approved 2022.05.11 · Insurance code 694003890
Improvement of glycemic control in patients with type 2 diabetes
This medication is used to assist in the control of blood sugar levels in patients with type 2 diabetes. The ingredients sitagliptin and metformin work together to effectively lower blood sugar. It is used as an adjunct to diet and exercise to improve blood sugar control. By continuously taking this medication, one can expect positive effects on maintaining stable blood sugar levels.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg extended-release tablet or the 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of two 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication contains sitagliptin and metformin and is used for diabetes treatment. First, due to the sitagliptin component, serious allergic reactions may occur; if symptoms such as rash, hives, or difficulty breathing appear, discontinue use immediately and consult a physician. Additionally, there is a rare but serious side effect of acute pancreatitis, which involves inflammation of the pancreas; if symptoms such as abdominal pain, vomiting, or severe stomach discomfort occur, inform medical personnel immediately. The metformin component, though rare, can cause a serious metabolic disorder known as lactic acidosis, which may present symptoms such as muscle pain, fatigue, difficulty breathing, or abdominal pain, thus caution is warranted. This medication is not to be administered in patients with significantly reduced kidney function, severe liver disease, acute cardiac conditions, or severe infections. Also, if receiving iodinated contrast agents for radiologic examinations, this medication should be discontinued for a certain period before and after the examination, and one should resume taking it only after confirming normal kidney function. This medication is not intended for use in pregnant or nursing women or children under 18 years of age. While taking this medication, maintaining regular meals and exercise is essential, and since hypoglycemia symptoms may occur, it is advisable to prepare sugar or glucose. Particularly, when taken together with insulin or other hypoglycemic agents, the risk of hypoglycemia increases; therefore, one should be aware of symptoms and may need to adjust medication dosage accordingly. Regular checks of kidney function, blood tests, and vitamin B12 levels are essential to ensure there are no abnormalities. Alcohol consumption can increase the risk of lactic acidosis, so it is advised to refrain from excessive drinking during the treatment. In case of surgery, this medication should be discontinued 48 hours prior to the surgery and resumed only after confirming that kidney function is normal post-operation. Lastly, if symptoms such as skin blisters or severe joint pain occur during the course of medication, one should consult a physician immediately for treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air exposure and should be kept at room temperature between 1°C and 30°C. This way, the medication's effectiveness can be safely maintained.
A pale blue, oval-shaped, bilaterally convex slow-release film-coated tablet.
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.